Korean Circ J.  2022 Jul;52(7):496-512. 10.4070/kcj.2022.0078.

Optimal Rhythm Control Strategy in Patients With Atrial Fibrillation

• Kim D
• Yang PS
• Joung B

• KMID: 2530731
• DOI: http://doi.org/10.4070/kcj.2022.0078

Abstract

For almost 20 years, data regarding the effect of rhythm control therapy for atrial fibrillation (AF) on cardiovascular prognosis in comparison with rate control therapy has not been conclusive. The safety of rhythm control and anticoagulation therapy has generally improved. Recently, it was revealed that a rhythm-control strategy reduced the risk of adverse cardiovascular events than usual rate control in patients with recent AF (diagnosed within 1 year). Within 1 year after the AF diagnosis, early initiation of rhythm control led to more favorable cardiovascular outcomes than rate control. Early rhythm control reduced the risks of stroke and heart failure-related admission than rate control. Moreover, rhythm control was associated with lower dementia risk than rate control. Finally, early rhythm control treatment was also effective in patients with asymptomatic AF but less effective in older adults. Therefore, in patients with AF, rhythm control should be considered at earlier stages, regardless of symptom.

Keyword

Atrial fibrillation; Rhythm control; Early treatment; Cardiovascular outcome; Cognitive outcome

Figure

• 

  Figure 1 Weighted cumulative incidence curves for individual components of the primary composite outcome in (A) early and (B) late atrial fibrillation treatments. Figure courtesy of Kim et al.47) AF = atrial fibrillation; CI = confidence interval; HR = hazard ratio.

• 

  Figure 2 Benefit-to-harm ratios of rhythm control compared with rate control according treatment timing. The ratios >1 indicate positive net benefit. Figure courtesy of Kim et al.47) AF = atrial fibrillation; CI = confidence interval.

• 

  Figure 3 Relation between treatment timing and risk of clinical outcomes for rhythm control or rate control in (A) overall period and (B) within 1 year after the first diagnosis of AF. Figure courtesy of Kim et al.47) The x-axis shows the timing of treatment initiation since the first diagnosis of AF; the y-axis, HRs associated with rhythm control compared with rate control. The black horizontal lines indicate HR=1, which corresponds to an equal risk of outcomes in patients treated with rhythm and rate control. Dashed black lines show the 95% CI.AF = atrial fibrillation; CI = confidence interval; HR = hazard ratio.

• 

  Figure 4 Relation between treatment timing and risk of ischemic stroke (A), hospitalization owing to heart failure (B), acute myocardial infarction (C), and cardiovascular death (D) for rhythm control or rate control. Figure courtesy of Kim et al.48) The x-axis shows the timing of treatment initiation since the first diagnosis of atrial fibrillation; the y axis, HRs associated with rhythm control compared with rate control. The skyblue horizontal dotted lines indicate HR=1, which corresponds to an equal risk of outcomes in patients treated with rhythm and rate control. Dashed black lines show the 95% CI.CI = confidence interval; HR = hazard ratio.

• 

  Figure 5 Relationship between age at treatment initiation and the risk of the primary composite outcome in early rhythm control and rate control groups. Figure courtesy of Kim et al.57) The x-axis shows the age at treatment initiation and the y-axis shows HRs associated with rhythm control when compared with rate control. The purple horizontal line indicates HR=1, which corresponds to an equal risk of outcomes in patients treated with rhythm control and rate control. The dashed black lines indicate the 95% CI.CI = confidence interval; HR = hazard ratio.

• 

  Figure 6 Weighted cumulative incidence curves for the primary composite outcome in patients aged <75 years (A) and ≥75 years (B) who were recently (within 1 year) diagnosed with atrial fibrillation. Figure courtesy of Kim et al.57) CI = confidence interval; HR = hazard ratio.

• 

  Figure 7 Weighted cumulative incidence curves for all-cause dementia in (A) overall and (B) after censoring stroke. Figure courtesy of Kim et al.74) CI = confidence interval; sHR = subdistribution hazard ratio.

• 

  Figure 8 Relation between age at treatment initiation and risk of dementia for rhythm control or rate control. Figure courtesy of Kim et al.74) The x-axis shows the age at the time of treatment initiation; the y-axis, HR associated with rhythm control compared with rate control. The purple horizontal line indicates HR=1, which corresponds to an equal risk of outcomes in patients treated with rhythm and rate control. Dashed black lines show the 95% CI.CI = confidence interval; HR = hazard ratio.

Reference

1. Joung B, Lee JM, Lee KH, et al. 2018 Korean guideline of atrial fibrillation management. Korean Circ J. 2018; 48:1033–1080. PMID: 30403013.

2. Timmis A, Townsend N, Gale CP, et al. European Society of Cardiology: cardiovascular disease statistics 2019. Eur Heart J. 2020; 41:12–85. PMID: 31820000.

3. Lee H, Kim TH, Baek YS, et al. The trends of atrial fibrillation-related hospital visit and cost, treatment pattern and mortality in Korea: 10-year nationwide sample cohort data. Korean Circ J. 2017; 47:56–64. PMID: 28154592.

4. Kim D, Yang PS, Jang E, et al. 10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population. Am Heart J. 2018; 202:20–26. PMID: 29802976.

5. Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015; 386:154–162. PMID: 25960110.

6. Kim D, Yang PS, Jang E, et al. Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006 through 2015. Heart. 2018; 104:2010–2017. PMID: 29666179.

7. Marijon E, Le Heuzey JY, Connolly S, et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation. 2013; 128:2192–2201. PMID: 24016454.

8. Camm AJ, Amarenco P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016; 37:1145–1153. PMID: 26330425.

9. Kim D, Yang PS, Yu HT, et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a population-based cohort. Eur Heart J. 2019; 40:2313–2323. PMID: 31212315.

10. Kim D, Yang PS, Jang E, et al. Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation. Europace. 2021; 23:184–195. PMID: 33063123.

11. Mark DB, Anstrom KJ, Sheng S, et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019; 321:1275–1285. PMID: 30874716.

12. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42:373–498. PMID: 32860505.

13. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019; 140:e125–e151. PMID: 30686041.

14. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002; 347:1834–1840. PMID: 12466507.

15. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347:1825–1833. PMID: 12466506.

16. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003; 41:1690–1696. PMID: 12767648.

17. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008; 358:2667–2677. PMID: 18565859.

18. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009; 360:668–678. PMID: 19213680.

19. Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019; 321:1261–1274. PMID: 30874766.

20. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018; 378:417–427. PMID: 29385358.

21. Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020; 383:1305–1316. PMID: 32865375.

22. Adelstein EC, Althouse AD, Davis L, et al. Amiodarone is associated with adverse outcomes in patients with sustained ventricular arrhythmias upgraded to cardiac resynchronization therapy-defibrillators. J Cardiovasc Electrophysiol. 2019; 30:348–356. PMID: 30575185.

23. Cosedis Nielsen J, Johannessen A, Raatikainen P, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med. 2012; 367:1587–1595. PMID: 23094720.

24. Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med. 2021; 384:316–324. PMID: 33197158.

25. Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med. 2021; 384:305–315. PMID: 33197159.

26. Kirchhof P, Andresen D, Bosch R, et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet. 2012; 380:238–246. PMID: 22713626.

27. Gillinov AM, Bagiella E, Moskowitz AJ, et al. Rate control versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J Med. 2016; 374:1911–1921. PMID: 27043047.

28. Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol. 2006; 48:2340–2347. PMID: 17161267.

29. Jaïs P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation. 2008; 118:2498–2505. PMID: 19029470.

30. Ganesan AN, Shipp NJ, Brooks AG, et al. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc. 2013; 2:e004549. PMID: 23537812.

31. Willems S, Meyer C, de Bono J, et al. Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation. Eur Heart J. 2019; 40:3793–3799c. PMID: 31755940.

32. Dinshaw L, Schäffer B, Akbulak Ö, et al. Long-term efficacy and safety of radiofrequency catheter ablation of atrial fibrillation in patients with cardiac implantable electronic devices and transvenous leads. J Cardiovasc Electrophysiol. 2019; 30:679–687. PMID: 30821012.

33. Talajic M, Khairy P, Levesque S, et al. Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. J Am Coll Cardiol. 2010; 55:1796–1802. PMID: 20413028.

34. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999; 341:857–865. PMID: 10486417.

35. Khan MN, Jaïs P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med. 2008; 359:1778–1785. PMID: 18946063.

36. Jones DG, Haldar SK, Hussain W, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol. 2013; 61:1894–1903. PMID: 23500267.

37. Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol. 2014; 7:31–38. PMID: 24382410.

38. Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation. 2016; 133:1637–1644. PMID: 27029350.

39. Prabhu S, Taylor AJ, Costello BT, et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study. J Am Coll Cardiol. 2017; 70:1949–1961. PMID: 28855115.

40. Yang PS, Kim D, Sung JH, et al. Reduction of mortality by catheter ablation in real-world atrial fibrillation patients with heart failure. Sci Rep. 2021; 11:4694. PMID: 33633286.

41. Packer DL, Piccini JP, Monahan KH, et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. Circulation. 2021; 143:1377–1390. PMID: 33554614.

42. Sohns C, Zintl K, Zhao Y, et al. Impact of left ventricular function and heart failure symptoms on outcomes post ablation of atrial fibrillation in heart failure: CASTLE-AF trial. Circ Arrhythm Electrophysiol. 2020; 13:e008461. PMID: 32903044.

43. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008; 1:62–73. PMID: 19808395.

44. Kirchhof P, Bax J, Blomstrom-Lundquist C, et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference ‘research perspectives in AF’. Eur Heart J. 2009; 30:2969–2977c. PMID: 19535417.

45. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol. 2003; 41:2197–2204. PMID: 12821247.

46. Kirchhof P, Breithardt G, Camm AJ, et al. Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial. Am Heart J. 2013; 166:442–448. PMID: 24016492.

47. Kim D, Yang PS, You SC, et al. Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study. BMJ. 2021; 373:n991. PMID: 33975876.

48. Kim D, Yang PS, You SC, et al. Comparative effectiveness of early rhythm control versus rate control for cardiovascular outcomes in patients with atrial fibrillation. J Am Heart Assoc. 2021; 10:e023055. PMID: 34889116.

49. Rolf S, Kornej J, Dagres N, Hindricks G. What can rhythm control therapy contribute to prognosis in atrial fibrillation? Heart. 2015; 101:842–846. PMID: 25792720.

50. Yang PS, Sung JH, Jang E, et al. Catheter ablation improves mortality and other outcomes in real-world patients with atrial fibrillation. J Am Heart Assoc. 2020; 9:e015740. PMID: 32427022.

51. Tsadok MA, Jackevicius CA, Essebag V, et al. Rhythm versus rate control therapy and subsequent stroke or transient ischemic attack in patients with atrial fibrillation. Circulation. 2012; 126:2680–2687. PMID: 23124034.

52. Shariff N, Desai RV, Patel K, et al. Rate-control versus rhythm-control strategies and outcomes in septuagenarians with atrial fibrillation. Am J Med. 2013; 126:887–893. PMID: 24054956.

53. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019; 74:104–132. PMID: 30703431.

54. Shah RU, Freeman JV, Shilane D, Wang PJ, Go AS, Hlatky MA. Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation. J Am Coll Cardiol. 2012; 59:143–149. PMID: 22222078.

55. Srivatsa UN, Danielsen B, Anderson I, et al. Risk predictors of stroke and mortality after ablation for atrial fibrillation: the California experience 2005-2009. Heart Rhythm. 2014; 11:1898–1903. PMID: 25048442.

56. Bunch TJ, May HT, Bair TL, et al. The impact of age on 5-year outcomes after atrial fibrillation catheter ablation. J Cardiovasc Electrophysiol. 2016; 27:141–146. PMID: 26443666.

57. Kim D, Yang PS, You SC, et al. Age and outcomes of early rhythm control in patients with atrial fibrillation: nationwide cohort study. JACC Clin Electrophysiol. 2022; 8:619–632. PMID: 35589174.

58. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013; 381:752–762. PMID: 23395245.

59. Villacampa-Fernández P, Navarro-Pardo E, Tarín JJ, Cano A. Frailty and multimorbidity: two related yet different concepts. Maturitas. 2017; 95:31–35. PMID: 27889050.

60. Rockwood K, Theou O, Mitnitski A. What are frailty instruments for? Age Ageing. 2015; 44:545–547. PMID: 25824236.

61. Gibbs H, Freedman B, Rosenqvist M, et al. Clinical outcomes in asymptomatic and symptomatic atrial fibrillation presentations in GARFIELD-AF: implications for AF screening. Am J Med. 2021; 134:893–901.e11. PMID: 33607088.

62. Steinberg BA, Gao H, Shrader P, et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. Am Heart J. 2017; 194:132–140. PMID: 29223431.

63. Willems S, Borof K, Brandes A, et al. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. Eur Heart J. 2022; 43:1219–1230. PMID: 34447995.

64. Yang PS, Sung JH, Jang E, et al. The effect of integrated care management on dementia in atrial fibrillation. J Clin Med. 2020; 9:9.

65. Joung B. Risk factor management for atrial fibrillation. Korean Circ J. 2019; 49:794–807. PMID: 31456373.

66. Kim D, Yang PS, Jang E, et al. Blood pressure control and dementia risk in midlife patients with atrial fibrillation. Hypertension. 2020; 75:1296–1304. PMID: 32172620.

67. Kim D, Yang PS, Joung B. Prevention of dementia in patients with atrial fibrillation. Korean Circ J. 2021; 51:308–319. PMID: 33821580.

68. Kim D, Yang PS, Joung B. Lower dementia risk with anticoagulation and ablation in patients with atrial fibrillation. International Journal of Arrhythmia. 2021; 22:17.

69. Chung MK, Shemanski L, Sherman DG, et al. Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy. J Am Coll Cardiol. 2005; 46:1891–1899. PMID: 16286177.

70. Jin MN, Kim TH, Kang KW, et al. Atrial fibrillation catheter ablation improves 1-year follow-up cognitive function, especially in patients with impaired cognitive function. Circ Arrhythm Electrophysiol. 2019; 12:e007197. PMID: 31442075.

71. Kim D, Yang PS, Sung JH, et al. Less dementia after catheter ablation for atrial fibrillation: a nationwide cohort study. Eur Heart J. 2020; 41:4483–4493. PMID: 33022705.

72. Bunch TJ, Crandall BG, Weiss JP, et al. Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J Cardiovasc Electrophysiol. 2011; 22:839–845. PMID: 21410581.

73. Kirchhof P, Haeusler KG, Blank B, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J. 2018; 39:2942–2955. PMID: 29579168.

74. Kim D, Yang PS, You SC, et al. Association of rhythm control with incident dementia among patients with atrial fibrillation: a nationwide population-based cohort study. Age Ageing. 2022; 51:afab248. PMID: 35061873.